Travatan Z (travoprost)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Travoprost, a synthetic analog of naturally occurring prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent.
Travoprost, a synthetic analog of naturally occurring prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent that is structurally and pharmacologically related to other agents in this class (e.g., latanoprost). Like latanoprost, travoprost acts as a selective prostanoid agonist and mimics the effects of PGF2alpha at its prostanoid receptor. Although the mechanism of action of travoprost has not been fully elucidated, the drug appears to reduce intraocular pressure (IOP) by increasing uveoscleral outflow of aqueous humor.
Travoprost is a prodrug and has little, if any, pharmacologic activity until hydrolyzed in vivo to travoprost free acid. A reduction in IOP generally occurs within 2 hours after topical application of travoprost and peaks within 12 hours.
USES: Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
Generic name: travoprost
Pronunciation: (TRA-voh-prost)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Travatan Z
Indications
The following indications are listed for Travatan Z:
- Ocular Hypertension
- Open Angle Glaucoma
Also known as: Chronic Glaucoma, Compensated Glaucoma, Glaucoma Simplex, Increased Intraocular Pressure, Increased Iop, Open-Angle Glaucoma, Raised Intraocular Pressure, Simple Glaucoma.
Dosing
The recommended adult dosage of travoprost for the treatment of open-angle glaucoma or ocular hypertension is 1 drop of a 0.004% ophthalmic solution in the affected eye(s) once daily in the evening. Travoprost 0.004% ophthalmic solution should not be administered more frequently than once daily since more frequent dosing may paradoxically diminish the intraocular pressure (IOP)-lowering effect of the drug.
If the target IOP is not achieved, alternative or additional ocular hypotensive agents may be required. (See Uses: Ocular Hypertension and Glaucoma.)
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No interactions with travoprost are currently known.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
The manufacturer states there are no known contraindications to the use of travoprost.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Ocular hyperemia occurred in approximately 30-50% of patients who received travoprost ophthalmic solution in clinical trials. Up to 3% of patients discontinued therapy because of conjunctival hyperemia. Decreased visual acuity, ocular discomfort, foreign body sensation, pain, and pruritus have been reported in approximately 5-10% of patients who received travoprost ophthalmic solution in clinical trials. Adverse ocular effects reported in approximately 1-4% of patients include abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing.
Adverse nonocular events reported in approximately 1-5% of patients include allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, GI disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infection.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Use of travoprost ophthalmic solution in pediatric patients younger than 16 years of age is not recommended because of potential safety concerns related to increased pigmentation following long-term use. (See Pigmentation under Cautions: Warnings/Precautions.)
Category C. (See Users Guide.)
Teratogenic effects, including skeletal, external, and visceral malformations, were observed in rats receiving IV travoprost at dosages up to 250 times the maximum recommended human ocular dosage but not following IV administration in rats or following subcutaneous administration in mice at dosages up to 75 or 25 times, respectively, the maximum recommended human ocular dosage. Increased postimplantation losses and decreased fetal viability were observed in rats and mice at dosages exceeding 75 and 7.5 times, respectively, the maximum recommended human ocular dosage. Increased postnatal mortality, decreased neonatal body weight gain, and adverse effects on neonatal development also have been observed in animal studies.
There are no adequate and well-controlled studies using travoprost ophthalmic solution in pregnant women. Travoprost ophthalmic solution should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
Travoprost and/or its metabolites are distributed into milk in rats; it is not known whether travoprost and/or its metabolites are distributed into human milk. Caution is advised when travoprost ophthalmic solution is used in nursing women.
No overall differences in safety and efficacy of travoprost ophthalmic solution have been observed between geriatric patients and younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.